Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update
News provided by
Share this article
Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions
HAMILTON, ON and BOSTON, May 11, 2021 /PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2021 and provided an update on clinical and corporate developments. We continue to advance our Phase 1 study of FPI-1434, said Chief Executive Officer John Valliant, Ph.D. In anticipation of data and determination of a recommended Phase 2 dose in the first half of 2022, we are amending the study protocol to define tumor-specific cohorts based upon IGF-1R expression and tumor uptake as seen to date in the Phase 1 study.
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
ACCESSWIRE
11 May 2021, 06:05 GMT+10
Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer
Announced encouraging preliminary data from a Phase 1b trial of gedatolisib plus Ibrance® and endocrine therapy for patients with ER+/HER2- metastatic breast cancer, in which gedatolisib showed a potentially differentiated safety and tolerability profile
Secured additional financing to strengthen cash position and provide funding for expanded clinical development activities
Entered into clinical trial collaboration agreements with leading cancer research centers, Novartis, Pfizer, and Puma to evaluate the efficacy of targeted therapies in patients selected with Celcuity s CELsignia Multi-Pathway Activity Test
Date Time
Share
Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind spatial atlas of early-stage lung cancer and surrounding normal lung tissue at single-cell resolution, providing a valuable resource for studying tumor development and identifying new therapeutic targets. The study was published today in Cancer Discovery, a journal of the American Association for Cancer Research.
The findings reveal a heterogeneous lung cancer ecosystem, with extensive interactions between cancer cells and the surrounding microenvironment that regulate early cancer development. By studying the crosstalk between the tumor and surrounding immune cells, researchers identified and validated CD24, an immune checkpoint protein, as a new immunotherapy target for lung cancer treatment.
Kim Reiss, MD
PHILADELPHIA More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance therapy, researchers from the Abramson Cancer Center at the University of Pennsylvania reported online today in the Journal of Clinical Oncology. The results from the phase II trial at the ACC support the use rucaparib for pancreatic cancer patients with BRCA1, BRCA2, and PALB2 variants to help control tumor growth without the aggressive side effects of chemotherapy.
Rucaparib a targeted therapy in pill form is currently approved by the U.S. Food and Drug Administration as a maintenance therapy for patients with recurrent ovarian and fallopian tube cancer and prostate cancer, but not pancreatic cancer.
Weill Cornell Medicine
Scientists have made major advances in understanding and developing treatments for many cancers by identifying genetic mutations that drive the disease. Now a team led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and the New York Genome Center (NYGC) has developed a machine learning technique for detecting other modifications to DNA that have a similar effect.
The study, published May 10 in Cancer Discovery, a journal of the American Association for Cancer Research, focuses on a type of chemical modification to DNA, called methylation, that typically silences nearby genes. The new technique can analyze the thousands of DNA methylation changes detected in tumor cells and infer which ones are likely driving tumor growth.